180 Wealth Advisors, LLC Viking Therapeutics, Inc. Transaction History

180 Wealth Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$9.24 - $19.64 $27,720 - $58,920	-3,000 Reduced 23.08%	10,000 $186,000
Q2 2023 Jul 11, 2023	SELL	$14.84 - $24.79 $14,840 - $24,790	-1,000 Reduced 7.14%	13,000 $210,000
Q1 2023 Apr 07, 2023	SELL	$8.08 - $17.33 $50,904 - $109,178	-6,300 Reduced 31.03%	14,000 $233,000
Q4 2022 Feb 02, 2023	BUY	$2.72 - $9.4 $816 - $2,820	300 Added 1.5%	20,300 $190,000
Q3 2022 Oct 12, 2022	BUY	$2.55 - $3.89 $7,649 - $11,670	3,000 Added 17.65%	20,000 $54,000
Q2 2022 Jul 11, 2022	BUY	$2.11 - $3.15 $35,870 - $53,550	17,000 New	17,000 $48,000

478

66.1M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of 180 Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on 180 Wealth Advisors, LLC with notifications on news.